Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis

Página do item simplificado
dc.contributor.authorCéspedes-Cruz, A.
dc.contributor.authorGutiérrez-Suárez, R.
dc.contributor.authorPistorio, A.
dc.contributor.authorRavelli, A.
dc.contributor.authorLoy, A.
dc.contributor.authorMurray, K. J.
dc.contributor.authorGertoni, V.
dc.contributor.authorWulffraat, N.
dc.contributor.authorOliveira, S.
dc.contributor.authorWalsh, J.
dc.contributor.authorCalvo Penades, I.
dc.contributor.authorAlpigiani, M. G.
dc.contributor.authorLahdenne, P.
dc.contributor.authorSaad-Magalhães, C. [UNESP]
dc.contributor.authorCortis, E.
dc.contributor.authorLepore, L.
dc.contributor.authorKimura, Y.
dc.contributor.authorWouters, C.
dc.contributor.authorMartini, A.
dc.contributor.authorRuperto, N.
dc.contributor.institutionPRINTO
dc.contributor.institutionServizio di Epidemiologia e Biostatistica
dc.contributor.institutionUniversità degli Studi
dc.contributor.institutionRheumatology Department
dc.contributor.institutionIstituto Gaetano Pini
dc.contributor.institutionWilhelmina Kinderziekenhuis
dc.contributor.institutionRoyal Alexandra Hospital
dc.contributor.institutionHospital Universitario La Fe
dc.contributor.institutionClinica Pediatrica
dc.contributor.institutionPediatric Rheumatology
dc.contributor.institutionOspedale Pediatrico Bambin Gesù
dc.contributor.institutionUniversita' degli Studi di Trieste
dc.contributor.institutionHackensack Medical Center
dc.contributor.institutionUniversity Hospital Gasthuisberg
dc.contributor.institutionCentro Medico Nacional La Raza
dc.contributor.institutionHospital General de México
dc.contributor.institutionInstituto de Puericultura e Pediatria Martagao Gesteira
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:22:48Z
dc.date.available2014-05-27T11:22:48Z
dc.date.issued2008-03-01
dc.description.abstractObjectives: To examine the change in health-related quality of life (HRQOL) and its determinants in children with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). Methods: Patients were extracted from the PRINTO clinical trial which aimed to evaluate the efficacy and safety profile of MTX administered in standard, intermediate or higher doses (10, 15 and 30 mg/m2/week respectively). Children with polyarticular-course JIA, who were less than 18 years and had a complete HRQOL assessment were included. Results: A total of 521 children were included. At baseline, patients with JIA showed poorer HRQOL (p<0.01) than healthy children. In 207/412 (50%) and 63 (15%) children, HRQOL values were 2 standard deviations below the mean of healthy controls in the physical and psychosocial summary scale, respectively. After 6 months of treatment with standard dose MTX, there was a statistically significant improvement in all HRQOL health concepts, particularly the physical ones. Similar improvements were observed in those who did not respond to a standard dose of MTX and were subsequently randomised to a higher dose. The presence of marked disability at baseline was associated with a fivefold increased risk of retaining poor physical health after 6 months of active treatment with standard dose MTX. Other less important determinants of retaining poor physical well-being were the baseline level of systemic inflammation, pain intensity and an antinuclear-antibody-negative status. Conclusions: MTX treatment produces a significant improvement across a wide range of HRQOL components, particularly in the physical domains, in patients with JIA.en
dc.description.affiliationIRCCS G Gaslini Pediatria II PRINTO, Genova
dc.description.affiliationIRCCSG Gaslini Servizio di Epidemiologia e Biostatistica, Genova
dc.description.affiliationIRCCS G Gaslini Pediatria II Università degli Studi, Genova
dc.description.affiliationFRACP Princess Margaret Hospital for Children Rheumatology Department, Perth, WA
dc.description.affiliationIstituto Gaetano Pini, Milan
dc.description.affiliationWilhelmina Kinderziekenhuis Department of Pediatric Immunology and Rheumatology, Utrecht
dc.description.affiliationRoyal Alexandra Hospital, Glasgow
dc.description.affiliationHospital Universitario La Fe, Valencia
dc.description.affiliationIRCCS G Gaslini Clinica Pediatrica, Genova
dc.description.affiliationHospital for Children and Adolescents Helsinki University Central Hospital Pediatric Rheumatology, Helsinki
dc.description.affiliationOspedale Pediatrico Bambin Gesù, Rome
dc.description.affiliationUniversita' degli Studi di Trieste, Trieste
dc.description.affiliationHackensack Medical Center, Hackensack, NJ
dc.description.affiliationUniversity Hospital Gasthuisberg, Leuven
dc.description.affiliationIRCCS G Gaslini Università di Genova PRINTO, Largo Gaslini, 5, 16147 Genova
dc.description.affiliationCentro Medico Nacional La Raza, México City
dc.description.affiliationResearch Division Hospital General de México, México City
dc.description.affiliationInstituto de Puericultura e Pediatria Martagao Gesteira, Rio de Janeiro
dc.description.affiliationFaculdade de Medicina de Botucatu Universidade Estadual Paulista, Botucatu
dc.description.affiliationUnespFaculdade de Medicina de Botucatu Universidade Estadual Paulista, Botucatu
dc.format.extent309-314
dc.identifierhttp://dx.doi.org/10.1136/ard.2007.075895
dc.identifier.citationAnnals of the Rheumatic Diseases, v. 67, n. 3, p. 309-314, 2008.
dc.identifier.doi10.1136/ard.2007.075895
dc.identifier.issn0003-4967
dc.identifier.lattes7098310008371632
dc.identifier.orcid0000-0002-7631-7093
dc.identifier.scopus2-s2.0-39549087440
dc.identifier.urihttp://hdl.handle.net/11449/70322
dc.language.isoeng
dc.relation.ispartofAnnals of the Rheumatic Diseases
dc.relation.ispartofjcr12.350
dc.relation.ispartofsjr7,699
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectmethotrexate
dc.subjectadolescent
dc.subjectchild
dc.subjectchild care
dc.subjectclinical feature
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdisability
dc.subjectdisease severity
dc.subjectdose response
dc.subjectdrug dose comparison
dc.subjectdrug response
dc.subjecterythrocyte sedimentation rate
dc.subjectfunctional status
dc.subjecthuman
dc.subjectjuvenile rheumatoid arthritis
dc.subjectmajor clinical study
dc.subjectpriority journal
dc.subjectquality of life
dc.subjectrandomized controlled trial
dc.subjectscoring system
dc.subjecttreatment outcome
dc.subjectwellbeing
dc.subjectAdolescent
dc.subjectAntirheumatic Agents
dc.subjectArthritis, Juvenile Rheumatoid
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectDisability Evaluation
dc.subjectDose-Response Relationship, Drug
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunosuppressive Agents
dc.subjectMale
dc.subjectMethotrexate
dc.subjectQuality of Life
dc.subjectRecovery of Function
dc.subjectSeverity of Illness Index
dc.subjectTreatment Outcome
dc.titleMethotrexate improves the health-related quality of life of children with juvenile idiopathic arthritisen
dc.typeArtigo
dcterms.licensehttp://group.bmj.com/group/rights-licensing/permissions/authorreprints
unesp.author.lattes7098310008371632[14]
unesp.author.orcid0000-0002-7631-7093[14]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Coleções

Artigos - Pediatria - FMB